Peter te Boekhorst – Research output — Erasmus University Rotterdam

View Scopus Profile

53 Article
2 Meeting Abstract
2 Comment/Letter to the editor
1 Review article

2 results

Filter

2024

A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial
Verstovsek, S., Talpaz, M., Wadleigh, M., Isidori, A., Te Boekhorst, P., Savona, M. R., Bose, P., Pozdnyakova, O., Mesa, R., El-Galaly, T. C., O'Sullivan, J., Gamel, K., Higgins, B., Katakam, S., Todorov, B., Trunzer, K. & Harrison, C. N., 1 Jun 2024, In: Haematologica. 109, 6, p. 1977-1983 7 p.
Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Open Access
File

1 Citation (Scopus)

1 Downloads (Pure)
2021

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
for the RESUME trialists, Apr 2021, In: Leukemia. 35, 4, p. 1197-1202 6 p.
Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

8 Citations (Scopus)